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ABSTRACT 
 
Title:  
The role of diffusion weighted magnetic resonance imaging and apparent diffusion 
coefficient quantification in the evaluation of pulmonary lesions which are indeterminate on 
contrast enhanced computed tomography. 
Aims and objectives:  
To assess the value of absolute signal intensity, lesion to spinal cord ratio (LSR) and apparent diffusion 
coefficient (ADC) values obtained from the solid and necrotic components of indeterminate pulmonary 
lesions in differentiating benign from malignant lesions.  
Materials and methods:  
Forty seven consecutive patients with indeterminate pulmonary lesions detected on contrast 
enhanced CT of  thorax who fulfilled the selection criteria for the study underwent MRI with 
T2 weighted and diffusion weighted imaging (DWI) (b= 0, 500, 1000 s/mm2). On DWI, the 
absolute signal intensity, signal intensity of the lesion as compared subjectively to that of the 
thoracic skeletal muscles (hypointense, isointense or hyperintense) and the LSRs (average of 
3 values) were obtained following which ADC values of the solid and necrotic parts of the 
lesion were assessed. The values for benign and malignant lesions and were compared using 
the independent samples T- test. Receiver operating characteristic curves (ROC) were plotted 
and diagnostic cut-off values were obtained.  
Results:  
Of the total of 47 patients enrolled (32 men; 15 women), 43 were diagnosed on histopathology 
and the rest, on sputum culture or follow up after antibiotic therapy. On performing a qualitative 
analysis comparing the signal intensity of the lesion on DWI (b=500 and 1000 s/mm2) to that 
of the thoracic skeletal muscle, most benign (N=27) and malignant lesions (N=20) were found 
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to be hyperintense on DWI with no statistically significant difference on b=500 s/mm2 images 
(p value = 0.590) and b= 1000 s/mm2 images (p value = 0.590). On comparing benign versus 
malignant lung lesions, statistically significant difference was seen between the absolute signal 
intensity of the solid component of the lesion on DWI (b=1000 s/mm2) (p value =0.002; 95% 
CI  2.04 to 105.22), LSR on DWI (b=500 s/mm2 (p value=0.002; 95% CI  0.24 to 0.97) and b= 
1000 s/mm2 (p value= 0.001; 95% CI 0.29 to 1.06)) and ADC of the solid component (p value= 
0.006; 95% CI 0.079 to 0.969  x 10-3 mm2/s). There was no statistically significant difference 
between absolute signal intensity values of benign and malignant lesions on b=500 s/mm2 
images (p value= 0.059; CI =105.22 to 2.04 x 10-3 s/mm2).  
For differentiation of malignant from benign lesions, ROC curves for LSR on DWI b=500 
s/mm2 yielded a cut-off value of 1.234 with 70.0% sensitivity and 74.1% specificity (AUC= 
0.761),  LSR on DWI b=1000 s/mm2 yielded a cut-off value of 1.141 with 70% sensitivity and 
85.2% specificity  (AUC = 0.765) and ADC values of the solid component yielded a cut-off 
value of 1.248 x 10-3 mm2/s with 80% sensitivity and 74.1% specificity (AUC= 0.735). Higher 
LSR values and lower ADC values are suggestive of malignancy. Some malignant lesions like 
mucinous adenocarcinoma (2/4) and squamous cell carcinoma (2/5) showed ADC values 
higher than the said cut-off value and a few cases benign lesions of tuberculosis (2/11), fungal 
infection (1/3) and a case of amyloidosis showed ADC values lower than that of the cut-off.  
12 of 27 benign and 5 of 20 malignant lung lesions had areas of necrosis with no significant 
difference in the ADC of the necrotic components in the two groups (p value= 0.132; 95% CI 
1.393 to 0.201 x 10-3 mm2/s).  
Conclusion:  
DWI is a useful, safe, non-invasive tool for evaluation of pulmonary lesions which are 
indeterminate on CT. LSR and ADC of solid component are useful for differentiating bening 
 
3 
 
from malignant lesions with no significant difference in diagnostic performance between the 
them (p value= 0.779). If a lesion tests positive for malignancy for either of the tests, the 
overall sensitivity can be increased up to 94% (specificity = 63.1%). In patients with high risk 
for lung biopsy, DWI & ADC maps in addition to CECT, can further assess the likelihood of 
malignancy and help direct further management. 
 
Keywords: diffusion weighted magnetic resonance imaging, b factor, absolute signal 
intensity, lesion to spinal cord ratio, apparent diffusion coefficient, indeterminate pulmonary 
lesions 
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INTRODUCTION 
 
With the advent of computed tomography (CT), there has been an increase in the number of 
pulmonary lesions detected in patients undergoing CT of thorax for related or unrelated 
reasons. In a patient detected to have a pulmonary lesion, it is vital to arrive at a diagnosis 
which would direct further management. CT of the thorax with contrast (CECT) has 
significantly improved the ability to localize and characterize pulmonary lesions over plain 
chest radiograph (1). It is often possible to arrive at a single diagnosis based on CT findings 
and the clinical presentation of the patient. However, in some cases, it may not be possible to 
further characterize the lesions and differential diagnosis could include infectious, 
inflammatory causes and malignancy.  
Lung lesions can be categorised on CT in to nodule, mass, cavity, consolidation and ground 
glass opacity. Both malignancy and infection can present as nodule, mass like lesion, cavity, 
consolidation and ground glass opacity. Most infectious and inflammatory lesions can be 
empirically treated based on imaging findings with corroborative clinical features and lab 
investigations. However, obtaining a tissue diagnosis is vital prior to initiating treatment of 
malignancy, for definitive diagnosis, obtaining the histopathological subtype, 
immunohistochemistry and genetic studies that direct surgery, chemotherapy and  
radiotherapy. Lung carcinoma is still one of the leading causes of cancer related death and early 
diagnosis is so important that developed countries have established screening methods for at-
risk population. 
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Diffusion weighted imaging (DWI) which has shown promising results in differentiating 
malignant from benign lesions in the brain and prostate is now being explored for its possible 
use in evaluating pulmonary lesions. There have been a few studies in the recent past which 
have looked at differences in DWI and ADC in biopsy proven benign and malignant lesions 
with promising results. On review of literature, we found no dedicated studies assessing the 
additional role of DWI to evaluate pulmonary lesions which cannot be diagnosed on CT as 
probably malignant or probably benign. When CT findings are equivocal, the use of 
advanced imaging help identify the cases where the risk to benefit ratio of performing lung 
biopsy is great. 
 
The purpose of this prospective study is to additionally characterize pulmonary lesions which 
are indeterminate on CT, using visual and quantitative analysis of DWI and ADC maps and 
reveal its role in contributing to diagnosis of malignancy versus infection. The final diagnoses 
in our patients were based on biopsy and histopathological examination, clinical follow up 
and other corroborative investigations. 
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AIMS AND OBJECTIVES 
 
Aim: 
To assess the role of diffusion weighted magnetic resonance imaging and apparent diffusion coefficient 
quantification in the evaluation of pulmonary lesions which are indeterminate on contrast enhanced CT 
of the thorax. 
 
Primary objectives: 
1. To assess the average ADC values from the solid component of the lesions and assess 
difference in ADC values between malignant and benign lesions.  
2. To obtain the absolute signal intensity of pulmonary lesions on DWI b=500 s/mm2and 
b=1000 s/mm2 images and assess the difference in absolute signal intensity between 
malignant and benign lesions. 
3. To obtain the lesion to spinal cord signal intensity ratio (LSR) and assess difference in 
LSR between malignant and benign lesions.  
4. To grade the signal intensity of pulmonary lesions on DWI images in comparison to the 
thoracic skeletal muscle and assess difference between that of malignant and benign 
lesions.  
 
Secondary objectives: 
1. To assess the difference in ADC values obtained from necrotic areas within benign and 
malignant lesions. 
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REVIEW OF LITERATURE 
 
In a patient detected to have a pulmonary lesion, it is vital to arrive at a diagnosis which would 
help direct further management, be it conservative follow up or aggressive medical or surgical 
treatment (1). Lung lesions can be categorised on CT in to consolidation, cavity, nodule, mass, 
and ground glass opacity. Malignancy, infection and inflammatory causes can have these 
appearances on CT. 
Consolidation 
 
Consolidation is a term used to describe filling of airspaces in the pulmonary tree with a 
material which increases its relative attenuation with that of the surrounding normal lung 
parenchyma (2). A consolidation is an area of increased lung parenchymal attenuation with 
obscuration of the pulmonary vessels (sometimes with an air bronchogram) without any 
significant volume loss of the affected segment. A ground glass opacity is defined as 
increased lung parenchymal attenuation without obscuration of the pulmonary vessels. The 
increase in parenchymal attenuation may occur due to filling of air-spaces with fluid 
(pulmonary edema), pus cells or other inflammatory cells (pneumonia), blood (haemorrhage), 
protein (alveolar proteinosis) or malignant cells (bronchoalveolar carcinoma). The 
distribution may be patchy (incomplete airspace filling with incontiguous areas of residual 
gas within alveoli), lobar (homogenous increase in attenuation of a lobe with clear delineation 
of adjacent normal lung) or multifocal. Definitive etiological diagnosis is determined by 
clinical presentation, microbiological and or histopathological correlation.  
Based on the pattern of involvement, the causes can be classified as  
1. Lobar  
a. Infectious -  bacterial pneumonia  
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b. Malignant - lung carcinoma with obstructive atelectasis or pneumonia, 
adenocarcinoma with endobronchial spread 
c. Vascular - contusion, infarction  
d. Others - organizing pneumonia, eosinophilic pneumonia, sarcoidosis  
2. Diffuse  
a. Edema – pulmonary edema (cardiogenic, renal), acute respiratory distress 
syndrome (ARDS), hypoalbuminemia 
b. Infection – Viral, Pneumocystis jiroveci,  staphylococcal 
bronchopneumonia  
c. Haemorrhage- Wegener’s granulomatosis, Henoch Schonlein purpura 
(HSP), systemic lupus erythematosis (SLE)  
d. Others – Acute hypersensitivity pneumonitis, pulmonary alveolar 
proteinosis etc., 
3. Multifocal  
a. Bronchopneumonia (Klebsiella, Staphylococcus, Legionella, Gram 
negative bacteria, tuberculosis)  
b. Vascular – septic emboli, Wegener’s granulomatosis  
c. Neoplasms- adenocarcinoma with endobronchial spread, lymphoma.  
d. Others- organizing pneumonia, eosinophilic pneumonia, lipophilic 
pneumonia  
 
Definitive etiological diagnosis is determined by clinical presentation, microbiological and or 
histopathological correlation. There are however, some radiological features that could point 
to the diagnosis in certain cases. Common radiological signs associated with infection include 
the air bronchogram sign, the tree in bud sign associated with endobronchial spread of 
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infection (bacterial, mycobacterial, fungal etc), the bulging fissure sign associated with 
Klebsiella pneumonia, air-fluid sign which may indicate an abscess within and the split 
pleural sign which indicates as associated empyema. The feeding vessel sign is suggestive of 
septic emboli, but can also be present in pulmonary metastases (3). 
Cavity 
Pulmonary cavities are air-filled space within a consolidation, mass or nodule and may be 
seen both on plain chest radiographs or CT. The causes of pulmonary cavities are as follows-  
 Infection 
o pulmonary tuberculosis  
o pulmonary bacterial abscess/cavitating pneumonia  
o septic pulmonary emboli 
 other rare infections (coccidioidomycosis, actinomycosis, nocardiosis , 
melioidosis, cryptococcosis)   
 Cavitating malignancy 
o primary bronchogenic carcinoma (especially squamous cell carcinoma) 
o cavitating pulmonary metastases (squamous cell carcinoma, adenocarcinoma, 
sarcoma, tumours of the gastrointestinal tract and breast) 
 Non-infective granuloma 
o rheumatoid nodules 
o granulomatosis with polyangitis 
 Vascular 
o pulmonary infarct 
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These lesions are typically thick walled (2-5mm). A study done by Honda et al (2007) 
showed that presence of a notch in a cavitatory nodule and irregular internal wall was more 
commonly associated with malignancy while the presence of satellite nodule, linear margins, 
associated bronchial wall thickening and surrounding ground glass attenuation were more 
commonly associated with benign nodules (4). Post contrast enhancement, on the other hand 
can be seen in the walls of both infectious and malignant cavitatory lesions. 
 
Nodule: 
Pulmonary nodules are solitary or multiple focal, radiographic opacities. A classic 
solitary pulmonary nodule (SPN) is defined as a single, spherical, well-circumscribed, 
radiographic opacity measuring less than or equal to 30 mm in diameter and is surrounded 
completely by aerated lung. Pulmonary nodules may be solid or sub-solid. The latter group is 
further subdivided into part- solid and pure ground glass nodule. A solid nodule is an air-
space opacification with higher density than the surrounding parenchyma which may obscure 
underlying bronchovascular structures while a ground glass nodule is an ill-defined area of 
high attenuation which does not obscure bronchovascular structure. Solid pulmonary nodules 
could represent various etiologies like-  
 Benign granulomas 
 Intrapulmonary lymph node  
 Focal scar  
 Primary lung malignancy  
 Pulmonary metastases 
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These nodules have considerable overlap in their radiological features and follow up based on 
size recommended by the Fleischner’s guidelines.  
 
Figure 1: Interstitial pneumonia with eosinophilic granulomas presenting as a solid left lower 
lobe pulmonary nodule in a patient.  
 Subsolid nodules (especially ground glass nodules) are often transient and are caused by 
haemorrhage or infection. However, persistent subsolid nodules could be representative of 
malignancy of the adenocarcinoma spectrum. 
A solitary pulmonary nodule  has been described by Erasmus et al as a ‘discrete, well-
circumscribed, rounded opacity less than or equal to 3 cm in diameter that is completely 
surrounded by lung parenchyma, does not touch the hilum or mediastinum, and is not 
associated with adenopathy, atelectasis, or pleural effusion’ . This is often an incidental finding 
on chest radiographs/ contrast enhanced CT. In most cases, a benign etiology, commonly 
infection, is considered most likely. However, the challenge lies in differentiating these lesions 
from early stage lung cancer in a non-invasively and cost-effectively as is possible.(5)  
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Shi et al (6) studied the relationship between the size of a SPN and the chance of malignancy 
in a cohort at high risk for lung cancer and found that nodules <4mm) were least likely to be 
malignant.  Central, popcorn like and laminated calcifications are likely to be of benign 
etiology. In a study by Henschke et al  (7), part-solid nodules were malignant in 63% of part-
solid nodules, 18 % of pure ground glass nodules and 7 % of solid nodules  were found to be 
malignant. Presence of intranodular fat is indicative of a hamartoma. On the other hand, 
margins that are spiculated / irregular and distortion or encasement of adjacent 
bronchovascular structures are more commonly associated with malignancy(8).  Post contrast 
enhancement of less than 15 HU is in favour of a benign lesion. A large number of lesion 
detected on CT, however, do not show features characteristic of either are and termed 
indeterminate. Thus there still remains a grey area of overlap in some lesional characteristics 
like attenuation values, presence of cavitation/ central necrosis and wall thickness among 
infectious and malignant lesions. Also, lesions like active granulomas and hypervascular 
benign tumors may show significant post contrast enhancement.  In such cases PET-CT, MRI 
are other investigative modalities used for further characterization of the lesions as benign or 
malignant (9). 
PET-CT, although known for its high sensitivity ( 95 %) has a low specificity (~81%) and 
granulomatous lesions (10) like those due to pulmonary tuberculosis may show false positive 
results, which is problematic in a country like India, which has a high prevalence of the 
disease .   
Consolidating the various studies evaluating pulmonary nodules, the Fleischner society has 
drawn up guidelines for the management of solitary pulmonary nodules, updated in 2017 
(11). This encompasses the professional opinions of an international consortium of 
pulmonologists, surgeons, pathologists and thoracic radiologists with new data and 
accumulated experiences.  
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Due to the overlapping features of benign and malignant pulmonary lesions manifesting as 
nodules, cavities, consolidations or masses on CECT, there is a need to use other imaging 
modalities and techniques, to differentiate between the two due to implications related to their  
management (including further imaging, need for biopsy and histopathological examination 
of these lesions which would direct treatment).  
 
Pulmonary infections 
Pulmonary infections are common pulmonary pathology. The appearance of these infections 
on CECT depend on the causative organisms, their mode of spread and the immune status of 
the host among other factors. These infections can spread through the tracheobronchial tree 
(through inhalation), via the pulmonary vessels (haematogeneously) or through continuous 
spread from adjacent structures.  
Bacterial infections 
Several virulent bacterial infections like that of Streptococcus pneumonia, Klebsiella sp., 
Haemophilis influenzae often manifest as lobar pneumonia. It often affects patients at 
extremes of ages, presenting as fever, productive cough and dyspnoea. Fibrosuppurative 
infiltrates fill the alveolar airspaces result in consolidation which imparts a homogeneous 
opacification of the lung tissue with no volume loss (which correspond to the pathological 
stages of red and grey hepatisation) on CT restricted to one or more lobes with and air-
bronchogram and sometimes, with a syn-pneumonic effusion(12). 
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Tuberculosis  
The imaging features of pulmonary tuberculosis (caused by Mycobacterium tuberculosis) 
vary depending on the host and whether it is a case of primary or post-primary tuberculosis. 
Patient often have low-grade or chronic symptoms and its radiological appearances are so 
varied that it sometimes results in diagnostic confusion it sputum examination does not yield 
the acid-fast bacilli.  
In those with primary pulmonary TB, in an immunocompetent patient, the initial caseating 
granuloma, calcified forming a Ghon’s focus (often peripherally located in the upper lobe or 
apical segment of the lower lobe), and may be associated with pleural effusion (commoner in 
adults). If, accompanied by mediastinal or hilar lymphadepathy, it is called a Ranke complex 
(which may be calcified in upto 35% of cases).  
Post-primary TB is a result of reactivation and more commonly manifests as cavitations (20-
45% of cases) and commonly involve the upper lobes (85%). The cavity may erode a nearby 
bronchus resulting in and air-fluid level within. Endobronchial spread results in a ‘tree-in 
bud’ appearance (branching peribronchial thickening with fine nodules) on HRCT and may 
be associated with hilar adenopathy. 
Miliary tuberculosis, which results from haematogeneous dissemination of the bacillus, 
appears on CT as 1-3 mm nodules of uniform size and distribution.  
In patients with co-existing HIV infection, which CD4 counts are between 350 and 200 cells/ 
mm3 the manifestations resemble that of post-primary tuberculosis while in those with counts 
below 200 cells/ mm3, military TB is more common with generalized lymphadenopathy (13) 
Atypical mycobacterial infections 
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Other mycobacterial pulmonary infections, of which Mycobacterium avium-intracellulare is 
the most common,  pulmonary manifestation seen on CT include ground-glass opacities, 
‘tree-in bud’ appearance associated with endobronchial spread, areas of patchy consolidation 
and bronchiectasis with bronchial wall thickening (‘tram-track sign’) and pleural thickening. 
These lesions tend to have a predilection for the upper lobe, right middle lobe and lingual 
(14).  
Fungal infections 
These are commonly seen in immunocompromized patients who are diabetic, on long term 
steroid therapy, immunosuppressants or chemotherapy and those with HIV infection with low 
CD4 counts. Etiological agents include molds like Aspergillus sp. (most common), yeasts like 
Candida sp., and dimorphic fungi like Histoplasma capsulatum, Coccidoides immitis, 
Blastomyces sp. etc. Pulmonary aspergillosis has varied radiological manifestations that 
depend largely on the immune response of the host.  
Allergic bronchopulmonary aspergillosis is a result of a hypersensitivity reaction to the same 
and commonly manifests on CT as transient pulmonary alveolar ground glass opacities or 
centrilobular nodules and mucus plugging resulting in the typical ‘finger-in glove’ 
appearance. Over a long period of time, it can result in bronchiectasis and scarring.  
Aspergillomas occur in immunocompetent patients with structurally abnormal lungs (i.e 
bronchiectasis, cavitation). It is a fungal ball formed by a mixture of fungal hyphae, reactive 
cellular debris and mucus within a cavity, with vascular granulation tissue within the walls 
(which results in haemoptysis). On CT this appears as a central rounded mass of soft tissue 
attenuation within a cavity, surrounded by an air-crescent (Monod sign) with mobility 
demonstrated on positional change.  
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Invasive aspergillosis is typically seen in immunocompromised host and may result in 
broncho-invasive or angio-invasive disease. Radiologically, broncho-invasive disease 
manifests as obstructive tracheobronchitis (characterized by bronchial wall thickening), 
bronchiolitis (imparting a ‘tree in bud appearance’) or bronchopneumonia (seen as 
peribronchial areas of patchy consolidation). Angio-invasive disease, seen in profoundly 
immunosuppressed patients, particularly in the setting of neutropenia (<500cell/mcL) post 
bone marrow transplant, typically manifests on HRCT as a nodule surrounded by ground 
glass opacitiy (which represents haemorrhage), known as the ‘halo-sign’ (12).  
Pneumocystis pneumonia  
The organism is a yeast-like atypical fungus that almost exclusively affecting 
immunocompromised hosts, especially HIV positive patients with a 200 cells/ mm3.  HRCT 
of the thorax shows predominantly perihilar pulmonary ground-glass opacities with a ‘crazy 
paving’ pattern of involvement with pneumatocoeles  
Viral infections 
These are causes by a host of RNA and DNA viruses, including the influenza viruses, the 
manifestations of which vary depending on the viral strain and host factors. On CT, the most 
common findings are bilateral peribronchial thickening in the perihilar regions with 
interstitial infiltrates and areas of patchy atelectasis and air-trapping(15).  
 
Non-infectious inflammatory lung disease  
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This is a group of benign inflammatory pulmonary conditions which encompasses airspace 
predominant, vascular predominant and interstitial predominant disease. The air-space 
predominant lesions and some combined air-space/ interstitial disease like sarcoidosis often 
mimic infectious and malignant pulmonary lesions on CECT or HRCT (16).  
 
Airspace predominant inflammatory lung disease 
Eosinophilic pneumonias, especially the chronic subtype, is seen in the setting of asthma or a 
hypersensitivity response to certain drugs or part of fungal infections. CT shows areas of non-
segmental peripherally located air-space consolidations and band like opacities parallel to the 
pleura which may later progress to fibrosis.  
Organizing pneumonia is a non-specific response to pulmonary injury. The more common 
radiological appearance on CT is that of peripheral bilateral lower lobe predominant 
consolidations with air bronchograms and subpleural sparing and the ‘atoll sign’ which is an 
area of ground glass opacity surrounded by a rim of consolidation is typically described in 
this condition. However, occasionally, it may present as multiple lung masses that are PET 
avid and mimic carcinoma, leading to diagnostic confusion in such cases. Most of these case 
often resolve without specific treatment.  
Langerhan cell histiocytosis and respiratory bronchiolitis associated interstitial lung disease 
are both associated with smoking (which is also associated with higher risk of malignancy). 
The conditions themselves, however, are benign and the patterns of involvement are in the 
form of micronodules, cystic or cavitatory lesions in LCH which responds to smoking 
cessation and centrilobular nodules (with or without emphysematous changes) in case of RB-
ILD.   
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Vasculitis  
This encompasses a group of inflammatory disorders mainly affecting the blood vessels of 
the lung and are often associated with systemic vasculitis. Among other subtypes mentioned 
in the Chapel Hill classification, they have varied appearances.  In ANCA associated 
vasculitis, pulmonary nodules and areas of consolidation with cavitation are common and 
may be accompanied by mediastinal or hilar adenopathy and pleural effusion while on the 
other hand, Churg-Strauss syndrome presents with transient nodule, ground-glass opacities or 
patchy areas of mosaic attenuation and inter-lobular septal thickening with no specific lobar 
predilection. These appearances, however, may not be diagnostic. Thus, the clinical 
presentation, serum markers and imaging findings together help reach a diagnosis in most 
cases (17).  
 
Sarcoidosis  
It is a benign inflammatory systemic disorder characterized by noncaseating granulomatous 
disease. Pulmonary and mediastinal involvement in seen in up to ~90% of cases of 
sarcoidosis. CT features include ground glass opacities, interlobular septal thickening with 
centilobular nodules, confluence of smaller nodules that may mimic a consolidation often 
with enlarged mediastinal and hilar lymph nodes and in later stages, honeycombing and 
tractional bronchiectasis. Nodular sarcoidosis, in particular, often resembles primary or 
metastatic lung cancer on CT and is avid on PET. Differentiating it from lung carcinoma is 
important as it heralds a good prognosis and responds well to corticosteroid therapy(18).  
 
Lung carcinoma  
Epidemiology 
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Lung carcinoma is one of the most common causes of cancer related deaths, worldwide, in 
the last few decades and the global burden of disease study done in 2020 estimates that the 
economic burden of healthcare related costs for lung cancer and substantial (19). The 
incidence of lung cancer is 1.8 million (as of 2012) and is the responsible for 1.6 million cancer-
related deaths that occur annually. It has a much lower  five-year survival rate  of 17.8% than 
most other causes of cancer (20).  
In India, alone, it constitutes 6.9% of newly detected cases of cancer and 9.3% of deaths 
related to cancer, especially among males, with a rising trend among females. The disease 
also occurs more commonly in the elderly, with more than 70% of death occurring after the 
age of 65. The highest incidence is reported in the state of Mizoram (females and males) at 
age adjusted rates of 28.3 per 100,000 males and 28.7 per 100,000 females. The incidence of 
lung cancer has also risen in Metropolitan cities like Chennai, Bengaluru and Delhi (21). 
Although lung cancer is strongly associated with smoking, there is an increasing incidence of 
non-smokers who are affected by the disease. Adenocarcinoma is the most common 
histological type among these patients who, more often, are females and in some Asian 
populations, constitute up to ~25% of the patients with lung cancer (22). The high incidence 
of pulmonary tuberculosis in India further increases the risk of lung cancer in the affected 
population due to the parenchymal scarring which occurs as a sequel to previous infection 
(23).  
 
Histopathology 
The histopathological types of lung cancer are broadly divided into small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC) which includes adenocarcinoma, squamous 
cell and large cell carcinoma. Squamous cell carcinoma is most strongly associated with 
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cigarette smoking. There has been a rising incidence of adenocarcinoma in the last few decades 
which has now overtaken squamous cell carcinoma as the most common type.  
With rapid improvements in molecular techniques, it is now of increasing importance to 
identify specific genetic mutations associated with the different types of lung carcinoma. 
Epidermal growth factor is a protein that stimulates tyrosine kinase. Up to 15% of patients in 
the USA have tested positive for epidermal growth factor receptor (EGFR) mutations. 
Overexpression of this receptor due to mutations in the tyrosine kinase domain of the EGFR 
gene, leads to increase tumour growth. This mutation is most often seen in non-smoking 
females with adenocarcinoma. In these patients treatment with targeted therapy using 
monoclononal antibodies like erlotinib can increase the response rate up to 70%. 
Other mutations of genes encoding K-Ras protein, anaplastic lymphoma kinase (ALK) have 
also been studied to develop targeted therapy for patients with these mutations.  
 
Environmental risk factors for lung carcinoma  
 
Smoking 
It is the most strongly associated risk factor which increases proportionately with the dose as 
confirmed in the landmark study by Doll and Hill (24). The tar and other components are 
carcinogenic which nicotine can promotes tumour growth.. It has been found that cessation of 
smoking decreases lung cancer risk (especially squamous cell and small cell carcinoma) 
which drops by 50% after a period of 15 years post cessation (25). 
 
Pollutants and other carcinogens 
Air pollutants are a proven risk factor for lung cancer. Particles of size less than 2.3micron 
are more strongly associated with increased risk of lung cancer. Among the materials 
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associated with occupational lung disease, asbestos exposure (especially to chrysolite fibres) 
is a known risk factor for both lung and pleural carcinoma (26).  
 
Influence of cell-type on radiological appearance of lung carcinoma 
Up to 2% lung tumours can have varied cellular composition (27) and multiple synchronous 
primary lung tumours of various histopathological types can co-exist (28). Despite these 
discrepancies, certain radiological appearances suggest certain histological types of lung 
carcinoma.  
Adenocarcinoma 
This tumour most commonly presents as a peripherally located solitary pulmonary mass and 
is often associated with large hilar lymphadenopathy. Some of these masses, at the time of 
diagnosis, may show evidence of mediastinal involvement.  
 
 
Figure 2: Superior Sulcus Tumor 
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It may present as a superior sulcus tumour, also known as a Pancoast tumour. This variety 
often invades the adjacent visceral and parietal pleura and the chest wall. Horner’s syndrome 
(ptosis, miosis, enophthalmos and loss of ciliospinal reflex) with neck, shoulder pain and 
wasting of the lumbrical muscles is secondary to invasion of the superior cervical 
sympathetic ganglion and lower roots of the brachial plexus, respectively.  
 
 
Figure 3: Consolidation in adenocarcinoma in situ  
Adenocarcinoma in situ, formerly known as bronchoalveolar carcinoma, can show varied 
radiological appearances. It may present as a solitary pulmonary nodule in up to 43 %, 
consolidation or multicentric disease. Its presentation as diffuse consolidation can be 
explained by its unique pattern of growth, as it uses the alveoli as scaffolding stroma upon 
which it can grow and spread. Certain types of adenocarcinoma metastases (from primary 
tumours like the colon, pancreas and biliary tree) also may have a similar appearance. 
Desmoplastic reaction may lead to a spiculated margin and pleural tags. Pseudo-cavitation is 
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another described appearance (29) characterized by a peripheral heterogeneously enhancing 
lung mass with central areas of lucency and irregular margins forming a star-like pattern.  
 
 
Figure 4: "CT angiogram sign" 
 
 
Figure 5: "Cheerios in the chest"- cavitatory pulmonary lesions 
 
Another radiological appearance on CT commonly associated with adenocarcinoma in situ or 
minimally invasive adenocarcinoma, is the “CT angiogram sign”. The pulmonary vasculature 
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appears prominent against the background of consolidated lung with relatively lower 
attenuation. Other differential diagnoses for this radiological sign include pulmonary 
lymphoma and post-obstructive pneumonia (30) 
Other radiological presentations include  
 Atelectasis  
 Expansile areas of consolidation without an air bronchogram  
 Multifocal cavitatory lesions (cheerios sign) which is unusual in adenocarcinoma in 
situ due to lower propensity to outstrip its blood supply and undergo necrosis and its 
tendency to preserve the pulmonary architecture (31). 
 
Squamous cell carcinoma (SCC) 
These tumours are most commonly central in location. They may originate from the epithelial 
lining of the main or lobar or segmental bronchi. They form proliferative growths which 
result in bronchial obstruction and subsequently erode the bronchial walls. 
Intraluminal tumours cause bronchial obstruction and post-obstructive collapse of the 
respective lobes. The resultant volume loss results in ipsilateral mediastinal shift and 
hemidiaphragmatic elevation with a juxta-phrenic peak (specifically, in cases associated with 
upper lobe collapse). This radiographic appearance was first described by Golden as seen on 
frontal chest radiographs. Collapse of the right upper lobe results in the same appearing dense 
and shifted centrally and upward with a centrally located mass causing expansion of the 
hilum. These two changes result in the formation of the reverse S-shape called the Golden S 
sign (32). Post-obstructive infective consolidation, on the other hand, differs in that there is 
relative preservation of volume.  
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Squamous cell carcinoma and adenocarcinoma can be associated with scar tissue occurring as 
a result of previous tuberculosis and other conditions. Enlargement of the scar on follow up 
images must raise the suspicion of carcinoma at the site of the scar (31).  
SCC can invade the surrounding structures in the mediastinum including the aerodigestive 
tract and encase the great vessels. These tumours also metastasize frequently to the bone, 
liver and adrenal glands by hematogenous spread. 
 
Small cell carcinoma  
These are highly malignant neuroendocrine tumours which metastasize early in the course of 
the disease, hence harbour a relatively poorer prognosis. Most tumours are centrally located 
and associated with mediastinal lymphadenopathy. Less commonly, they may present as a 
peripherally located solitary pulmonary nodule, which carries a better prognosis.  
 
Figure 6: Small cell carcinoma of the right upper lobe with ipsilateral mediastinal 
lymphadenopathy (33) 
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Large cell undifferentiated carcinoma  
These constitute nearly 10% of the cases of lung cancer. Histopathologically, they lack 
squamous, glandular or small-cell differentiation. These tumours grow rapidly, are large in 
size, often, peripherally located and associated with necrosis.  They can potentially invade the 
pleura resulting in malignant pleural effusion and metastasize early.  
Bronchial carcinoid 
Bronchial carcinoid tumours are neuroendocrine lung tumours which originate in the 
bronchial or bronchiolar epithelium. They are typically endobronchial nodules or hilar or 
perihilar masses causing bronchial obstruction and post-obstructive collapse or consolidation. 
They show marked arterial phase enhancement due to rich vascular supply and may present 
with carcinoid syndrome due to secretion of various peptide hormones and neuroamines. 
(34). The peripheral, type, however, is a rare presentation, more commonly associated with 
smoking, that presents as a 10-30mm solitary pulmonary nodule with non-specific imaging 
features and are more often not associated with carcinoid syndrome. Although most cases are 
18 FDG-PET avid, up to a fourth of these lesions may not show increased uptake(35).   
 
Pulmonary lymphoma  
Pulmonary lymphoma is lung parenchymal lymphomatous involvement. It may be primary or 
secondary. Primary pulmonary lymphoma is rare and often a type a non-Hodgkin lymphoma. 
It presents as a pulmonary mass or mass-like consolidation with or without lymphadenopathy 
which may be associated with pleural effusion. Secondary pulmonary lymphomas are more 
common and represent secondary involvement of the lung in a case of Hodgkin or Non-
Hodgkin lymphoma. Pulmonary lymphoma may also present in the post-transplant setting or 
in patients with AIDS(36).  
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Screening for lung cancer 
 
Chest radiograph  
It is the earliest tool used for lung cancer screening. Although cost-effective and readily 
available at most centres, it is limited by its lower sensitivity and specificity. A few trials, 
carried out in Japan studied the use of chest radiographs as a screening tool and concluded 
that, in conjunction with sputum cytology, it conferred some advantage in early cancer 
detection and 5-year survival rates over no screening, but with no overall advantage for long 
term (20 year) survival (37),(38). 
 
CT screening  
With the advent of low-dose techniques, the use of CT in screening for lung cancer has been 
extensively studies. These studies looked at high-risk populations. The first few studies 
performed in Japan (39). In these studies, follow up of detected nodules was based on size 
(large nodule were subject to biopsy/ FNAC, nodule of intermediate size were screened at 
defined intervals and very small nodules were not followed up). This, along with later studies 
like Henschke et al’s  “Early Lung Cancer Action Project” (7) showed that lung cancer 
diagnosed at earlier stage using CT for screening had better treatment response and prognosis 
that those detected at later stages. 
 
With earlier CT image acquisition techniques, the accuracy was limited. However, with 
improving technology, namely multi-detector CT (which can produce 1mm contiguous 
sections) and reconstruction techniques like maximum intensity projection, there has been 
improved conspicuity of pulmonary nodules. Computer-aided Diagnosis (CAD) improves the 
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radiologist’s detection of nodules, while allowing the latter to use his/her discretion to deem 
them as clinically significant. Whatever be the technique, radiologists, world over use 
standard diagnostic and reporting guidelines like those laid out by the Fleischner Society.  
 
Diffusion weighted imaging  
Diffusion weighted imaging is a technique in MRI that is based on differential Brownian 
motion of water molecules in various tissue and helps evaluation the micro-architecture of these 
tissues. Intracellular water molecules have greater diffusion restriction than free water. Thus 
depending on the tissue architecture, degree of cellularity and the varying proportions of 
intracellular and extracellular compartments, the degree of diffusion restriction also varies 
between tissues and also between pathological areas within the a tissue against its normal 
background . Certain high grade malignancies and tissues that have undergone acute infarction 
show diffusion restriction due to the increased proportion of intracellular to extracellular water 
molecules. Diffusion weighted imaging thus helps qualitatively and quantitatively identify and 
measure diffusion restriction.   
 
The advent of magnetic resonance imaging in modern clinical medicine in the 1970s is credited 
to Lauterbur, Ernst R and Mansfield (40) Diffusion weighted imaging (DWI) was the result of 
research efforts of doctors like Tanner, Stejskal and Le Bihan who tried to differentiate 
malignant liver tumours from angiomas (41). Susceptibility to respiratory motion artefacts 
were, however, a major limitation. With the advent of echo-planar imaging and higher 
magnetic field strengths (1.5T, 3T) clinically useful diffusion weighted imaging of the 
abdomen and thorax became a reality due to shorter imaging time and increased signal to noise 
ratio.  
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In order to obtain a DWI sequence, a diffusion sensitization gradient is applied on both sides 
of the 180 degree refocussing pulse. The ‘b value’ a measure of the degree of applied diffusion 
weighting. It is represented by the following equation –  
b = γ² G² δ² (Δ−δ/3) 
G = amplitude  
δ = time of applied gradients  
Δ = duration between paired gradients  
 
Therefore, larger ‘b values’ may be obtained by widening the time interval between paired 
gradient pulses and increasing the duration and gradient amplitude.   
Therefore, to detect smaller lesions and slower moving water molecules within their 
intracellular compartments, a higher ‘b value’ is considered more suitable (i.e. b= 500 to 1000 
s/mm2). ADC values are calculated using a dedicated software and a parametric map generated 
which reflects the degree of diffusion restriction by drawing regions of interest (ROIs) on the 
map. An ideal choice of b value would be such that-  
B value X ADC ~ 1. 
Tissues with restricted diffusion are hyperintense in diffusion weighted images and 
hypointense on the corresponding ADC map.  Accepted ADC values depend on the tissue being 
imaged and the pathology.  
MRI techniques used for pulmonary diffusion weighted imaging 
Takahara et al(42) used a technique a technique to perform whole body MRI  using  STIR 
sequences with  higher b factors. It was also found that free breathing technique with STIR and 
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10 excitations produce good fat suppression and higher signal to noise ratio (SNR) than other 
techniques like breath hold techniques with 2 excitations and chemical shift selective pulse.    
 
Application of DWI in lung malignancy  
Malignant tumours have increased cellularity and are biologically aggressive. DWI has been 
used to help diagnose tumours in various organs in the body as a tool for both qualitative and 
quantitative assessment.  
Qualitatively, the images can be visually assessed for relative increase in signal intensity of the 
lesion on comparison with normal tissue enabling both detection and, to some extent, 
characterization of the lesion (43). There have been a studies that have proven the effectiveness 
of DWI in helping visually, differentiate malignancy from post-obstructive lung collapse (44) 
and benign nodules (45)  based on signal intensity. However, lesion characteristics were not 
typical of either and could not be used to differentiate between the two.  
Quantitative assessment of the lesion can be done by ADC calculation, which is related to the 
diffusion of water molecules within the intracellular and extracellular components of the lesion. 
In most malignant lesions, the ADC values are reduced. This can be attributed to increased 
cellular density within the tissue.  Additionally, the altered cell membranes, organelles, 
intracellular cytoskeleton and macromolecular composition also play a role in contributing 
towards diffusion restriction within these lesions. (46).  Many studies have shown a significant 
relationship between low ADC values with renal, hepatic, prostate and certain brain tumours 
(47,48).  
There are a few studies that have proven that the mean value of ADC for benign lesions is 
higher than that for malignant lesions(1,45,49). Few have also studied the relationship between 
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lesion to spinal cord ratio and compared with absolute ADC measurement of the lesions 
concluding that the latter showed better correlation (50).  
A study conducted by Liu et al (50) recruited sixty two patients who underwent DWI for 
evaluation of benign and malignant pulmonary lesions and compared the signal intensity of the 
lesion with that of skeletal muscle (b=500 s/mm2) and found no statistically significant 
difference between benign and malignant lesions. However, Uto et al (2009) in their study of 
67 patients compared lesion to spinal cord ratio (LSR) on DWI (b=1000 s/mm2) and ADC and 
found that LSR > 1.135 was found to have an accuracy of nearly 85.7 % in diagnosing 
malignant lesions (51). Gumustas et al (2012) later conducted a study on 62 patients who 
underwent DWI and the absolute signal intensity of the lesion of interest (SI) was estimated on 
DWI ( b=1000) and signal intensity of >277  in malignant lesions showed a sensitivity of 93 
%, specificity of 69 % and positive predictive value of 85 % (52). 
Mori et al (2008), in a study including 140 pulmonary nodules, showed that lesions with an 
ADC less than 1.1x 10ˉ³mm²/s were significantly more likely to be of malignant etiology (53). 
Similarly  Liu et al (2010) in a study including 66 patients with pulmonary nodules (12 benign 
and  54 malignant)  showed that a cut-off ADC value of more than 1.4 x 10ˉ³ mm²/s to represent 
a benign lesion, showed a sensitivity of 83.3% and a specificity of 74.1% (50).  
In the context of lung malignancies, the role of diffusion weighted magnetic resonance imaging 
in predicting the invasiveness of the NSCLC has also been assessed by Kanauchi et al (2009). 
In this study performed on a total of 41 patients with NSCLC (10 invasive and 31 non-
invasive), the lesion to spinal cord ratio was found to be an independent predictor of invasive 
lung carcinoma with a sensitivity of 90% and a specificity of 81%. (54).  
In another study which looked at the correlation of PET with diffusion weighted imaging by 
Tyng et al (2018), there was found to be a significant inverse correlation between ADC values 
on diffusion weighted MR images and SUVmax on PET images (p<0.001).  
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Presence of necrosis within both malignant and infectious lesions significantly alters the ADC 
value. Karaman et al(55) compared the wall/ necrosis ratio of benign infectious to malignant 
lesions and found the  cut-off value of 1.12 showing sensitivity of 100% & specificity of 98% 
specificity for malignancy with good intra and inter-observer reliability. 
 
Role of DWI and ADC in differentiating types of malignancy 
 
In order to determine disease prognosis, staging and guide treatment, lung cancer can be 
classified as SCLS (small cell lung carcinoma) and NSCLC (non-small cell lung carcinoma). 
SCLS, apart from merely, its unique histopathological appearance and immune-histochemical 
markers, unlike NSCLC is more aggressive, often presents with metastases or para-neoplastic 
syndromes at the time of diagnosis and is associated with a poorer prognosis (56).  There are 
also significant differences between the treatment options for both types. While surgery is the 
preferred treatment for stages 1- 3A for NSCLC, unresectable non-small cell carcinoma 
required chemo-radiation (57). 
 
Therefore, it is of vital importance to obtain a histopathological diagnosis prior to initiating 
treatment. This, however, poses some challenges and limitations. Trans-bronchial biopsies for 
peripherally located lesions and those with a diameter < 2cm, sufficient representative samples 
may not be obtained and sensitivity (in case of negative bronchoscopy) could be as low as ~ 
40% (58)  and CT guided biopsy, although more suited for peripherally located tumours is 
fraught with complications like pneumothorax and haemorrhage.  
 
Also, of particular interest, is the discovery of targeted therapy for the treatment of 
adenocarcinoma, a type of NSCLC. Epidermal growth factor receptor (EGFR) exists on the 
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cell surface and is activated by binding of its specific ligands, including epidermal growth 
factor and transforming growth factor α (TGFα).  Mutations that lead to EGFR overexpression 
(up regulation) or over activity have been associated with a number of cancers. Without kinase 
activity, EGFR is unable to activate itself, which is a prerequisite for binding of downstream 
adaptor proteins. Ostensibly by halting the signalling cascade in cells that rely on this pathway 
for growth (EGFR tyrosine kinase inhibitors), tumour proliferation and migration is 
diminished. (59) .  
 
Diffusion weighted imaging, carries the inherent advantage of being non-invasive and not 
exposing the patient to ionizing radiation, hence its importance increased further in patients 
who are unable to undergo biopsy. A study conducted by Matoba et al (2007) which recruited 
30 patients with lung carcinoma showed a significant difference in ADC value in squamous 
cell carcinoma and large cell carcinoma compared to benign lesion ( p< 0.05), and a 
significantly higher ADC value in well differentiated compared to moderately and poorly 
differentiated carcinoma ( p<0.05) (60).  
 
The purpose of this study is to characterize indeterminate pulmonary lesions on DWI images 
and evaluate the usefulness of ADC quantification in contributing to its diagnosis on 
comparison with clinical follow up, biopsy and histopathological examination or other 
corroborative investigations.  
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MATERIALS AND METHODS 
 
Design of data collection:  
• Outpatients and inpatients who undergo CECT thorax were identified.  
• Those patients who satisfied the inclusion criteria for the study were identified and 
recruited after ruling out exclusion criteria and obtaining informed consent. 
• MRI of the thorax was performed in the Radiology department with a Siemens 1.5 T 
MRI machine. 
• The scan was reported by the principal investigator using a standardized format 
• Final diagnosis was obtained through biopsy, other corroborative investigations and 
follow up.  
• Patients without a definite final diagnosis or lost to follow up were excluded from the 
study. 
 
Cases:  
Patients with indeterminate pulmonary lesions based on CECT thorax in the time period 
between October 2016 and September 2018 (2 year period). 
 
Methodology:  
Forty seven consecutive patients with indeterminate pulmonary lesions detected on CECT 
thorax who fulfilled the selection criteria for the study underwent T2 weighted imaging, 
diffusion weighted imaging (b=0, b=500, b=1000 s/mm2) and ADC quantification after 
informed consent.  
Inclusion criteria:  
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 Patients >18 years of age who had undergone CECT of the thorax showing indeterminate 
pulmonary lesions  
 Lesion with greatest diameter > 1cm  (nodules or mass or masses or cavity or consolidation)  
 Reported as ‘could be infection or malignancy’  
Exclusion criteria:  
 Patients who have already undergone biopsy of the lesion of interest that may alter the 
signal intensity of lesion on MRI. 
 Patients who have already undergone any treatment in the form of surgery or 
chemotherapy or radiotherapy or other medical treatment that may alter the 
pulmonary lesion. 
 Patients for whom MR imaging is contra-indicated due to the presence of aneurysmal 
clips, pacemakers, defibrillators that are not MRI compatible 
 Patients with severe claustrophobia, conditions that preclude ability to lie supine 
within the gantry (examples: severe orthopnoea secondary to pulmonary, cardiac or 
other causes), uncooperative patients or those requiring sedation or anaesthesia to 
undergo the procedure 
  Patients who have both infection and malignant lung pathology 
 Patients with motion artefacts that would impair image interpretation  
 
Outcome measures:  
DWI images: A region of interest (ROI) was chosen from the pulmonary lesion (largest 
possible diameter with no area of necrosis or foci of air) and another from the spinal cord (at 
least 10mm2) and the LSR was estimated. The signal intensity of the pulmonary lesion (in an 
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area devoid of necrosis or foci of air) was also visually compared to that of the thoracic 
skeletal muscle and noted as 
 1- hypointense 
 2- isointense  
 3- hyperintense 
  
ADC map: Rounded or elliptical ROI with an area of at least 10mm² was chosen from the 
solid area of the lesion with no areas of necrosis or foci of air and another ROI from an area 
of necrosis if present in the lesion. 
 
Study population recruitment: 
Sample size calculation:   
Based on study of Gumustas Sevtap et al (20), the formula for comparison of means between 
the two groups 
N = (Z 1-a/2 + Z 1-ᵝ/2)2 2 σ2  
                  (M1 - M2)2             
 
Z 1-a/2 = Z value for the required alpha error 
Z 1-ᵝ/2 = Z value for the required beta error 
σ = known standard deviation of the measure 
(M1-M2) = desired precision = difference in the known mean values of the two groups 
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N = Number of observations in each group (benign versus malignant) = 16 per group 
Sample selection: 
The study was conducted in the Department of Radiology, Christian Medical College and 
Hospital, Vellore from the period between October 2016 and September 2018. 
Forty seven consecutive patients were included in this MRI study of indeterminate pulmonary 
lesions who fulfilled the inclusion criteria without exclusion criteria. The patients took part 
voluntarily and signed the informed consent. 
Sampling strategy: 
Consecutive patients fulfilling the eligibility criteria and willing to take part in the research 
project voluntarily were recruited for the study 
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Design of data collection: 
Prospective observational study 
Data sources: 
The CECT thorax images and report of the patients who underwent scan in the department of 
Radiology were assessed by the principal investigator and guide for the presence of 
indeterminate pulmonary lesions to identify cases to be included in the study.  
The final diagnosis was obtained by histopathological examination of the biopsy specimen 
from the lesion obtained by image guidance or bronchoscopy or surgery and other 
corroborative investigations like sputum smear or culture, blood culture, serum markers and 
by follow up imaging documentation of resolution of the lesion on treatment with antibiotics 
or steroid. 
Thoracic MRI study: 
Machine: 1.5T Siemens MRI machine 
MRI sequences: With the patient in supine position, the following sequences were obtained: 
1. Respiratory gated T2-weighted images were obtained in the axial plane using the 
following parameters: TE/ TR-92/2000ms; matrix-324 x 384; slice thickness -6 mm; 
gap-0.6 mm. 
2. Diffusion weighted images (DWI) was obtained with b values of 0, 500 and 1000 
s/mm2 
3. ADC quantification was done using an in-built software  
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In the diffusion weighted images, the signal intensity of the lesion of interest (without 
necrotic areas or foci of air) was compared to that of the thoracic skeletal muscle as being 
hypointense, isointense or hyperintense. 
Diffusion weighted images (b=0, b=500 and b=1000 s/mm2) were then taken and the lesion to 
spinal cord signal intensity ratio was then estimated. 
ADC value was quantified from the regions of interest within the solid and necrotic 
components of the lesion. The results were then compared to the final diagnosis obtained by 
biopsy, other corroborative investigations and clinical findings. 
Personnel: 
Reporting of T2 weighted, diffusion weighted images and ADC maps was done by the 
principal investigator and approved by the thesis guide (Professor). 
The biopsy of the lesion was performed under bronchoscopic guidance (Pulmonary medicine 
department) or ultrasound or CT guidance (Radiology department)  
The histopathological and cytological examination of the specimens were done be done by a 
pathologist (Pathology department) 
The culture of the specimen was done in the microbiology department. 
Statistical methods: 
All baseline continuous variables were expressed in terms of mean ± standard deviation and 
all categorical variables were reported using frequencies and percentages. The mean LSR and 
ADC between benign and malignant lesions and their subgroups were compared using the 
independent samples T- test. Differences were considered significant at p<0.05. ROC curves 
were then plotted and cut-off values obtained to differentiate benign and malignant 
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pulmonary lesions and their respective sensitivities and specificities were calculated. All the 
statistical analysis were performed using SPSS 16.0 
Interpretation 
During interpretation of the MR images, the principal investigator and thesis guide were 
blinded to the results of biopsy, corroborative investigations and details of clinical follow up. 
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RESULTS 
 
The study comprised of a total of 47 patients with indeterminate pulmonary lesions detected 
on CECT of the thorax.   
Demographic profile of the participants  
The patients enrolled in this study were of the age group 24-79 years with mean age of 50 
years. The largest group of patients were in the age group 50-59 years (Figure 7).  
 
 
 
Figure 7: Column graph demonstrating age distribution of patients  
 
Of the total of 47 patients enrolled, there were 32 men and 15 women. The patients for the 
study were referred from the departments of general medicine, pulmonary medicine and 
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medical oncology. The distribution of patients based on the department of referral is as given 
in Table 1.   
 Table 1: Distribution of patients enrolled in the study according to department of referral 
Department of Referral No. of Patients Percentage (%) 
General Medicine 
8 17.02 
Pulmonary Medicine 
34 72.34 
Medical Oncology 
5 10.64 
Total  
47 100.00 
 
 
Final diagnosis 
Of the total of 47 patients, 43 underwent biopsy. The final diagnosis was obtained for 2 
patients by confirmation on sputum culture and TB PCR test and for the remaining 2 patients 
on follow up imaging within a month showing significant resolution of the lesion on 
treatment with short course of empirical non-antimycobacterial antibiotics.  
Among the 43 patients who underwent biopsy, 32 underwent CT guided biopsy, 10 
underwent transbronchial biopsy and 1 underwent thoracoscopic guided biopsy (Figure 8).  
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Figure 8: Distribution of patients according to method of biopsy (N=43) 
 
Of the 47 patients, the lesions in 27 patients (57.4%) were confirmed as benign and the lesions 
in 20 patients (42.6%) were confirmed as malignant.  
 
Figure 9: Stacked column graph depicting division of patients based on diagnostic categories  
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Among the 20 patients with malignant lesions, the types of malignant lesions included were as 
noted in Table 2. 
Table 2: Distribution of type of malignant pulmonary lesions based on biopsy (N=20) 
 
 
Type of malignancy No. of patients Percentage (%) 
Adenocarcinoma 
11 55 
Squamous cell carcinoma 
4 20 
Undifferentiated carcinoma 
2 10 
Lymphoma 
2 10 
Large cell carcinoma 
1 5 
Total 
20 100 
  
Among the 11 patients with biopsy proven adenocarcinoma of the lung, testing for EGFR 
mutations was performed on 6 patients, 1 of which tested positive and 5 were negative. 
Among the 20 patients with pulmonary lesions secondary to an infective cause, the distribution 
of causative pathogens was as noted Figure 11. Fifty percentage of these cases were 
tuberculosis. 
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Figure 10:  Distribution of infection based on the causative pathogen 
 
Among the cases of non-infectious benign pulmonary lesions, there was 1 case of pulmonary 
amyloidosis and 1 case of IgG4 disease, the rest being non-specific inflammatory lesions.  
 
Clinical Profile 
The mean duration of symptoms was 9.31 and 7.70 months for benign and malignant lesion 
with no significant difference between the two groups (p = 0.637).  29.6% of the patients with 
benign pulmonary lesions and 40% of the patients with malignant pulmonary lesions had 
history of smoking. Three of the 11 cases of adenocarcinoma (27.2%) had history of smoking 
as compared to 3 of the 4 cases of squamous cell carcinoma (75%). The symptom profile of 
the patients included in the study and the distribution of smokers in each of these groups are as 
described in tables 3 and 4 respectively.  
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Table 3: Symptom profile of patient with benign and malignant pulmonary lesions 
 
 
Table 4: Distribution of smokers versus non-smokers  
  Benign Malignant 
Non-smoker 19 12 
Smoker 8 8 
Total  27 20 
 
 
 
 
 
 
Symptom profile Benign Malignant 
Cough 25(92.6%) 17(85%) 
Expectoration 17(63%) 7(35%) 
Chest pain  8(29.6%) 6(30%) 
Breathlessness 16(59.3%) 10(50%) 
Haemoptysis  16(59.3%) 7(35%) 
Fever  9(33.3%) 5(25%) 
Sig. weight loss 12(44.4%) 8(40%) 
Total  27 20 
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Characteristics of the pulmonary lesions on CT  
Of the 47 patients, the pulmonary lesion (in case of multiple, the largest lesion) were seen to 
be located predominantly in the right lung (59.5%)) and lower lobes (46.8%). Most lesions 
were solitary (73%)) and unilateral 91.5%). The average of the maximum diameters of the 
lesions was 5.28cm. 44.4% of benign and 25% of malignant lesions had areas of necrosis.  
Of the total of 47 cases, 40 (85.1%) had ipsilateral mediastinal lymphadenopathy, 34 (72.3%) 
cases had ipsilateral hilar lymphadenopathy, 10 (21.3%) had contralateral mediastinal 
lymphadenopathy and 2 (4.2 %) had contralateral hilar lymphadenopathy. 11 patients (23.4 %) 
had associated with pleural effusion.   
 
Figure 11: Pie charts demonstrating the distribution of type of lesion in benign versus malignant 
lesions  
 
Of the 27 benign pulmonary lesions, most lesions were areas of consolidation (40.74%) and 
nodules (22.2%)). A few cases of infection and one case of IgG4 disease presented as mass like 
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lesions. The distribution of benign pulmonary lesions according to CT appearance is as shown 
in Table 5. 
 
Table 5: CT appearance of benign lesions  
Final Diagnosis 
  
Type of lesion  Total 
  
Nodule Mass Consolidation 
Thick walled 
cavity 
Tuberculosis 3 1 5 2 11 
Fungal infection 0 1 1 1 3 
Other bacterial infection 2 1 3 1 7 
Non-specific inflammation 1 0 1 1 3 
Hydatid 0 1 0 0 1 
Amyloidosis 0 0 1 0 1 
IgG4 disease 0 1 0 0 1 
Total  6 5 11 5 27 
 
Of the 20 malignant lesions, most cases of adenocarcinoma presented as areas of consolidation 
(54.5%). The distribution of various malignant pulmonary lesions according to their CT 
appearance is as shown in Table 6.  
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Table 6: CT appearance of malignant lesions  
Final Diagnosis Type of lesion  
 Total   Nodule Mass Consolidation Thick walled cavity 
Adenocarcinoma 2 3 6 0 11 
Squamous cell 
carcinoma 0 2 1 1 4 
Large cell carcinoma  0 1 0 0 1 
Lymphoma 0 1 1 0 2 
Undifferentiated 
carcinoma 0 0 2 0 2 
Total  2 7 10 1 20 
 
Characteristics of the pulmonary lesions on MRI 
Most benign and malignant lesions appeared as hyperintense on DWI with no statistically 
significant difference on b=500 s/mm2 images (p value = 0.590) and b= 1000 s/mm2 images (p 
value = 0.590) (Tables 7, 8).  
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Table 7: Comparison of signal intensity of lesion to that of thoracic skeletal muscle in benign 
versus malignant pulmonary lesions on DWI with b=500 s/mm2 
 
  
Signal Compared To Skeletal Muscle 
 (b=500 s/mm2) 
Total 
  
p value  
Hypointense Isointense Hyperintense 
Benign  
1 7 19 27  
 
0.590 
Malignant  
0 4 16 20 
Total 
1 11 35 47 
 
 
Table 8: Comparison of signal intensity of lesion to that of thoracic skeletal muscle in benign 
versus malignant pulmonary lesions on DWI with b=1000 s/mm2 
 
 
  
Signal Compared to Skeletal Muscle 
(b=1000 s/mm2) Total 
  
 
p value  
Hypointense Isointense Hyperintense 
Benign  
1 7 19 27  
 
0.590 
Malignant  
0 4 16 20 
Total 
1 11 35 47 
 
On comparing benign (N=27) versus malignant (N=20) lung lesions, there was a statistically 
significant difference between the signal intensity values of the solid component on b=1000 
s/mm2 (p value =0.002; 95% CI  105.22 to 2.04 s/mm2), LSR on b=500 s/mm2 (p value=0.002; 
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95% CI 0.97 to 0.24) and b= 1000 s/mm2 (p value= 0.001; 95% CI 1.06 to 0.29) and ADC 
value of the solid component (p value= 0.006; 95% CI 0.969 to 0.079 x 10-3 mm2 /s)  as 
demonstrated in Table 9.  
There was no statistically significant difference between signal intensity values of malignant 
and non-malignant lesions on b=500 s/mm2images (p value= 0.059; CI =105.22 to 2.04).  
 
Table 9: Comparison of signal intensity of solid component of lesion, LSR and ADC of solid 
component between malignant & benign lesions using the independent sample T test (N=47) 
 
    
  
N 
  
Mean 
  
SD 
  
p value 
95% CI 
    Upper Lower 
SI value on 
DWI (b=500 
s/mm2)  
Benign 27 132.17 86.49 
0.059 
 
105.22 
 
2.04 
 Malignant 
20 183.76 95.14 
SI value on 
DWI (b=1000 
s/mm2)  
Benign 27 72.01 38.11 
0.002 
 
80.69 
 
18.13 
 Malignant 
20 121.42 67.65 
LSR(DWI 
b=500 s/mm2)  
Benign 27 0.92 0.45 0.002 
 
0.97 
 
0.24 
 Malignant 20 1.52 0.78 
LSR(DWI 
b=1000 s/mm2)  
Benign 27 0.90 0.43 0.001 
 
1.06 
 
0.29 
 Malignant 20 1.58 0.86 
ADC (sol.) 
(X 10-3 mm2/s) 
Benign 27 1.438 0.465 
0.006 0.111 0.621 Malignant 20 1.072 0.399 
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Figure 12: Box plot showing significant difference in average signal intensity of the solid 
component in benign versus malignant lesions on DWI (b= 1000 s/mm2) (p value =0.002; 
95% CI 18.13 to 80.69) 
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Figure 13: Box plot showing significant difference in LSR on DWI (b= 500 s/mm2) in benign 
versus malignant lesions (p value=0.002; 95% CI 0.97 to 0.24) 
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Figure 14: Box plot showing significant difference in LSR on DWI (b= 1000 s/mm2) in 
benign versus malignant lesions (p value= 0.001; 95% CI 0.29 to 1.06) 
 
The outlier values of 3.875 on LSR (b=500 s/mm2) and 4.111 on LSR (b=1000 s/mm2) were 
that of a cases of mucinous type of adenocarcinoma.   
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Figure 15: Box plot showing significant difference in the ADC of the solid component in 
benign versus malignant lesions (p value= 0.001; 95% CI 0.111 to 1.621 x 10-3 mm2/s) 
 
Of the 20 cases of malignancy, some malignant lesions like mucinous adenocarcinoma (2/4) 
and squamous cell carcinoma (2/5) showed ADC values higher than the said cut-off value and 
among the 27 cases of benign lesions, few cases of tuberculosis (2/11), fungal infection (1/3) 
and a case of amyloidosis showed ADC values lower than that of the cut-off.  
Of the total of 47 cases, 12 of the 27 benign lung lesions and 5 of the 20 malignant lung lesions 
had areas of necrosis. There was found to be no significant difference in the apparent diffusion 
coefficient of the necrotic components in the two groups (p value= 0.132; 95% CI 1.393 to 
0.201 x 10-3 mm2/s).  
Of the 27 cases of benign pulmonary lesions, 11 lesions were due to tuberculosis and 10 were 
due to non-tubercular infections (fungal, hydatid, other bacterial infections) and other 
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conditions like amyloidosis and IgG4 disease. There was found to be no significant difference 
in signal intensity on DWI for b=500 s/ mm2 and b=1000 s/ mm2, lesion to spinal cord ration 
for b=500 s/ mm2 and b=1000 s/ mm2 images or in the ADC values of the solid component of 
the tuberculous versus other benign lesions, as shown in Table 10.  
 
Table 10: Comparison of mean signal intensity on DWI (b=500 and b=1000 s/ mm2), LSR 
(b=500 and b=1000) and ADC (solid component) between tuberculosis and non-tuberculous 
lesions using the independent samples T-test (N=24) 
 
  N 
 
Mean 
  
SD 
  
p value 
95% CI 
Upper Lower 
SI value on 
DWI (b=500 s/ 
mm2)  
Tuberculosis 
11 107.87 75.679 
0.233 110.13 28.11 
Other benign lesions 
16 148.88 91.756 
SI value       
DWI (b=1000 
s/ mm2)  
Tuberculosis 
11 67.7 41.509 
0.635 38.49 23.93 
Other benign lesions 
16 74.981 36.688 
LSR             
(DWI b=500 s/ 
mm2)  
Tuberculosis 
11 0.937 0.449 
0.853 0.337 0.40 
Other benign lesions 
16 0.903 0.465 
LSR              
(DWI b=1000 
s/ mm2)  
Tuberculosis 
11 1.041 0.396 
0.163 0.102 0.57 
Other benign lesions 
16 0.805 0.431 
ADC                  
(solid 
component) x 
10-3  mm2/s  
Tuberculosis 
11 1.326 0.430 
0.307 0.56 0.18 
Other benign lesions 
16 1.515 0.486 
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Among the 20 malignant lung lesions, there was also found to be no significant differences in 
the above parameters between adenocarcinoma and other malignancies as demonstrated in 
Table 11.  
 
Table 11: Comparison of means of signal intensity on DWI (b=500 and b=1000), Lesion to 
spinal cord ratio (b=500 and b=1000 s/ mm2) and ADC (solid component) between 
adenocarcinoma and other malignancies using the independent samples T-test (N=13) 
 
   N Mean SD p value 
95% CI 
Upper Lower 
SI value on 
 DWI (b=500 
s/ mm2)  
Adenocarcinoma 
11 169.93 98.72 0.292 
 
147.8 
 
47.38 
 
Other malignancies 7 220.14 89.07 
SI value on 
 DWI 
(b=1000 s/ 
mm2)  
Adenocarcinoma 
11 114.03 73.71 0.415 
 
97.13 
 
42.1 
 
Other malignancies 7 141.54 56.97 
LSR (DWI 
b=500 s/ 
mm2)  
Adenocarcinoma 
11 1.52 0.96 0.872 
 
0.89 
 
0.77 
 
Other malignancies 7 1.58 0.49 
LSR (DWI 
b=1000  s/ 
mm2)  
Adenocarcinoma 
11 1.61 1.09 0.994 
 
0.93 
 
0.93 
 
Other malignancies 7 1.61 0.47 
ADC 
(solid 
component)  
Adenocarcinoma 
11 1.06 0.45 0.598 
 
0.54 
 
0.32 
 
Other malignancies 7 1.17 0.35 
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In differentiating benign and malignant pulmonary lesions, using diffusion weighted imaging, 
the highest sensitivity was achieved with an ADC cut-off of 1.248 X 10-3 mm2/s (sensitivity - 
80%; specificity~ 74.1%) (Table 18) and the highest specificity was achieved with LSR on 
DWI (b=1000 s/ mm2) cut-off value of 1.275 (sensitivity ~ 70 %; specificity ~85.2 %) (Table 
17). The ROC curves for LSR (b= 500 s/ mm2 and b= 1000 s/ mm2) and ADC are as shown in 
Figures 12, 13 and 14 respectively.  
  
 
 
Figure 16: ROC curve for diagnostic performance of LSR (on DWI b=500 s/ mm2) for 
differentiation of malignant from benign pulmonary lesions. Cut-off value of 1.234 had a 
70.0% sensitivity and 74.1% specificity for differentiating the two. (AUC= 0.761) 
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Table 12: Diagnostic performance of LSR values on DWI (b=500 s/ mm2) for differentiation 
of malignant from benign pulmonary lesions (N=47) 
 
Area under the curve 0.761 
LSR (b=500 s/ mm2) 1.234 
False positive 7 
False negative 6 
Sensitivity 70% 
Specificity 74.1% 
Accuracy 72.34% 
Pos. predictive value 68.2% 
Neg. predictive value 76% 
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Figure 17: ROC curve for diagnostic performance of LSR (on DWI b=1000 s/ mm2) for 
differentiation of malignant from benign pulmonary lesions. Cut-off value of 1.141 had a 
70% sensitivity and 85.2% specificity for differentiating the two (AUC = 0.765) 
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Table 13: Diagnostic performance of LSR values for differentiation of malignancies from 
benign pulmonary nodules in DWI b=1000 s/ mm2 images (N=47) 
 
Area under the curve 0.765 
LSR (b=1000 s/ mm2) 1.141 
False positive 4 
False negative 6 
Sensitivity 70% 
Specificity 85.20% 
Accuracy 78.72% 
Pos. predictive value 77.78% 
Neg. predictive value 79.31% 
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Figure 18: ROC curve for diagnostic performance of ADC values for differentiation of 
malignancies from benign pulmonary lesions. Cut-off value of 1.248 X 10-3 mm2/s had a 80% 
sensitivity and 74.1% specificity for differentiating the two. (AUC= 0.735). 
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Table 14: Diagnostic performance of ADC values (from the solid component of the lesion) 
for differentiation of malignancies from benign pulmonary lesions (N=47) 
 
Area under the curve 0.705 
ADC cut off 1.248 X 10-3 mm2/s 
False positive 7 
False negative 4 
Sensitivity 80% 
Specificity 74.1% 
Accuracy 76.6% 
Pos. predictive value 69.6% 
Neg. predictive value 83.3% 
 
In order to improve the overall sensitivity of detection of malignancy in an indeterminate 
pulmonary lesion, the cut-off values for LSR on DWI (b=1000 X 10-3 mm2/s) and the ADC 
value were tested in parallel using ‘AND’ and ‘OR’ operators and the results are as described 
in Table 18.  If the criterion for diagnosing malignant pulmonary lesion was both to have an 
LSR (b=1000 s/ mm2) >= 1.141 and ADC (solid component) value of <= 1.248 X 10-3 mm2/s, 
the specificity of the test was raised to 96.2%. However, if the criteria for diagnosing the same 
was to have either of the two, the sensitivity of the test was raised to 94%.      
Table 15: Testing of LSR (b=1000 s/ mm2) and ADC cut-off values obtained in parallel  
 Sensitivity (%) Specificity (%) 
Using the ‘AND’ operator 56.0 96.2 
Using the ‘OR’ operator 94.0 63.1 
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CASE SERIES: 
Case 1:   
61 year old man with chronic idiopathic thrombocytopenic purpura on treatment with cough 
and breathlessness for 2 weeks 
 
Figure 19: CECT axial section showing an irregular lesion in the right upper lobe with 
spiculated margins  
 
Figure 20: T2W MR axial section showing an irregular heterogeneously T2 isointense lesion 
in the right upper lobe  
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Figure 21: Diffusion weighted images showing no diffusion restriction (isointense on DWI 
and ADC images). The values obtained from ROI placed within the solid areas shows the 
following values.  
 
Lesion to spinal cord ratio (b=500) = 0.481 (< 1.234) and lesion to spinal cord ratio (b=1000) 
= 0.731 (<1.141) 
ADC = 1.287 x 10-3 mm2/s (>1.243 X 10-3 mm2/s) 
Final diagnosis = Tuberculosis  
Case 2:   
60 year old smoker with an incidentally detected pulmonary nodule 
 
Figure 22:  CECT axial section HR cuts shows a solitary pulmonary nodule in the right lower 
lobe 
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Figure 23: T2W MR axial section showing an T2 isointense nodule in the right lower lobe 
 
 
Figure 24: Diffusion weighted images showing diffusion restriction (hyperintense on DWI 
with corresponding dark areas on ADC).The values obtained from ROI placed within the 
solid area shows the following values.  
 
Lesion to spinal cord ratio (b=500) = 2.028 (> 1.234) and lesion to spinal cord ratio (b=1000) 
= 2.472 (>1.141) 
ADC = 1.033 X 10-3 mm2/s (<1.243 X 10-3 mm2/s) 
Final diagnosis = Squamous cell carcinoma 
 
69 
 
Case 3:   
A 36 year old man with history of cough and haemoptysis for 1 month. 
 
 
Figure 25: CECT axial section showing an irregular heterogeneously enhancing lesion in the 
left upper lobe with central non-enhancing necrotic areas. 
 
 
Figure 26: T2W MR axial section showing an irregular heterogeneously T2 hyperintense 
lesion in the left upper lobe with central T2 hypointense areas. 
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Figure 27: Diffusion weighted images showing peripheral diffusion restriction (hyperintense 
on DWI with corresponding dark areas on ADC) with central T2W hypointense areas 
showing no restriction. The values obtained from ROI placed within the solid areas shows the 
following values.  
 
Lesion to spinal cord ratio (b=500 s/ mm2) = 1.833 (> 1.234) and lesion to spinal cord ratio 
(b=1000) = 1.649 (>1.141) 
ADC = 1.465 X 10-3 mm2/s (>1.243 X 10-3 mm2/s) 
Final diagnosis = Granulomatous inflammation with fungal hyphae (Aspergillus)  
 
Case 4: 
A 63  years  old  man  with  complaints  of  cough,  streaky  hemoptysis,  fever,  loss of 
appetite  for  the  past  6  months. 
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Figure 28: Contrast enhanced CT axial section (lung window) showing scattered sub-solid 
nodules and areas of consolidation predominantly involving the left lower lobe.  
 
 
Figure 29: T2W axial sections through the thorax showing T2 hyperintense areas of 
consolidation predominantly involving the left lower lobe.  
 
 
72 
 
 
Figure 30: Diffusion weighted images showing T2 shine through effect. The valued derived 
from the ROIs placed in the areas of consolidation area as shown below.  
 
Lesion to spinal cord ratio (b=500) = 0.622 (< 1.234) and lesion to spinal cord ratio (b=1000) 
= 0.534 (<1.141) 
ADC= 2.041 x 10-3 mm2/s (>1.243 x 10-3 mm2/s) 
Final diagnosis = Mucinous adenocarcinoma  
(Note: The mucinous type of adenocarcinoma, due to its high intracellular mucin content has 
a high signal intensity on T2WI with T2 shine though effect on DWI and ADC, hence, unlike 
other malignancies, has a low LSR and high ADC value) 
 
 
 
 
 
 
 
 
 
 
73 
 
DISCUSSION 
 
Pulmonary lesions can have various appearances on CT which includes nodule, mass, 
consolidation and cavity. The disease conditions associated with these CT appearances are 
many and are as detailed in Table 16.    
 
Table 16: Benign and malignant causes for commonly encountered pulmonary lesions  
 
 Benign  Malignant  
Consolidation  Lobar 
 Infectious -  pneumonia  
 Vascular - contusion, infarction  
 Others - organizing pneumonia, 
eosinophilic pneumonia, sarcoidosis 
Diffuse  
 Pulmonary edema, ARDS, 
hypoalbuminemia 
 Infection – Viral, Pneumocystis 
jiroveci,  bronchopneumonia 
 Haemorrhage- Wegener’s 
granulomatosis, Henoch Schonlein 
purpura (HSP) 
 Others – Acute hypersensitivity 
pneumonitis, pulmonary alveolar 
proteinosis etc 
 Lung carcinoma 
with obstructive 
atelectasis  
 Adenocarcinoma  
Thick walled 
cavity  
 Infection 
o Pulmonary tuberculosis 
o Bacterial abscess, cavitating 
pneumonia  
o Septic emboli  
o Other rare infections  
(coccidiomycosis, 
actinomycosis etc)   
 Non-infective granulomas 
o Rheumatoid nodules 
o Granulomatosis with 
polyangitis  
 Vascular 
 Primary lung 
carcinoma 
(especially 
squamous cell 
carcinoma) 
 Cavitating 
pulmonary 
metastases 
(squamous cell 
carcinoma, 
adenocarcinoma, 
sarcoma etc) 
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o Pulmonary infarct 
 Benign Malignant 
Nodule or 
Masses 
 Benign granulomas 
 Inflammatory pseudotumour, 
sarcoidosis, amyloidosis etc  
 Intrapulmonary lymph node  
 Focal scar  
 Primary lung 
malignancy  
 Pulmonary 
metastases 
 
 
In many cases, CECT helps in differentiating benign from malignant lesions based on 
morphology of the lesion and associated findings. However, in some cases the lesions are 
indeterminate based on CT features and lesions cannot be characterized as benign or 
malignant. In such patients, other imaging techniques may help in further characterization.  
Qualitative or visual assessment of conventional sequences like T1W and T2W images can 
help determine the cellular characteristics of the lesion to a certain extent. DWI and ADC 
maps may further help to characterize the lesions at cellular level and could potentially help 
objectively differentiate between benign and malignant lesions which has major implications 
on management and prognosis. On DWI, relaxation time on T2 weighted imaging and the 
corresponding ADC value of that voxel, together determine the signal. Its utility has already 
been explored and used in the diagnosis of malignancies of other organs like the brain, liver 
and prostate (62–64). Apparent diffusion coefficient mapping allows quantification of the 
magnitude of diffusion of water molecules within a tissue (65). The values may be obtained 
from a region of interest placed within a given slice. Restricted diffusion is indicated by 
correspondingly lower ADC values and depends on the relative proportion of extracellular to 
intracellular water content, integrity of the cell membrane, the intracellular organelles and 
presence of soluble macromolecules in the cytoplasm. The ADC value is found to be low in 
tissues with high cellular density and those within cells having a higher mitotic index (66). As 
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a result, malignancies tend to have high signal intensity on diffusion weighted imaging and 
low ADC value. 
Our study assessed the role of diffusion weighted imaging and ADC quantification in 
diagnosing pulmonary lesions which are indeterminate on CECT. In our study, the signal 
intensity of the lesion was compared with that of the thoracic skeletal muscle in DWI on a 
three point scale (hypointense, isointense and hyperintense) and most benign and malignant 
lesions were found to be hyperintense with no statistically significant difference (p value = 
0.590 on b=500 and p value = 0.590 on b=1000). Liu et al (50) who studied 62 patients with 
66 pulmonary lesions in a similar three point scale (hypointensity, moderate intensity and 
hyperintensity) comparing with skeletal muscle found no significant statistical difference 
between malignant and benign lesions. However they concluded that malignant lesion tends 
to show hyperintensity and benign lesions tends to show moderate intensity. 
 
A study by Satoh et al (45) which used a 5-point rank scale comparison of lesion to spinal 
cord signal intensity on DWI with b=1000 for differentiation of malignant and benign 
pulmonary nodules showed significant difference (p <0.01) with 0.796 AUC of ROC and 
threshold score of 3 with sensitivity of 88.9% and specificity of 79.6%. A few cases of 
metastatic nodules and adenocarcinoma showed lower scoring and a few granulomas and 
other inflammatory nodules showed high score in their study. Another study which made a 
similar comparison  on 5 point scale was by Cakir et al (1). They assessed 48 solitary 
pulmonary nodules of which 30 were malignant and 18 were benign. Their study showed a 
slightly higher sensitivity and specificity of 93.3% and 88.9% for LSR score of 3 or more. 
 
Our study included quantitative assessment of absolute signal intensity and LSR on DWI 
with b=500 and b=1000, and ADC quantification. On comparison of mean absolute signal 
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intensity of the lesions on DWI, malignant lesions showed a higher value on b=500 s/mm2 
and b=1000 s/mm2 images. Higher b value images of 1000 s/mm2 which allows higher signal 
to noise ratio and probably better characterization showed statistically significant difference 
in mean absolute signal intensity unlike b= 500 s/mm2 in our study.  
 
The lesion to spinal cord ratio and ADC quantification are more objective methods. LSR is 
obtained by dividing the absolute signal intensity of the lesion by that of the spinal cord in 
that section. In our study there was found to be a significant difference between the means of 
LSR on DWI b=500 (p value=0.002) with a sensitivity of ~ 70% and a specificity of ~ 74.1% 
for a cut- off value of 1.234 and on b= 1000 (p value= 0.001) with a sensitivity of ~ 70% and 
a specificity of ~ 85.2% for a cut-off value of ~ 1.141. Higher LSR values indicate higher 
chances of lesion being malignant. On using ADC value of the solid component to 
differentiate between benign and malignant lesions, our study showed statistically significant 
difference (p value= 0.006). Using a cut-off ADC value of 1.248 x 10-3 mm2/s, the sensitivity 
was 74.1% and specificity was 76.6% with area under the curve of 0.735 in ROC analysis. 
Lower ADC values indicate higher change of a lesion being malignant. Other studies which 
made a similar comparison were those by Cakmak et al (68) which studied 47 patients with 
62 pulmonary lesions of which 42 were malignant and 20 were benign. Their study showed a 
sensitivity and specificity of 69% and 85% respectively for LSR cut off value of 0.86 and 
sensitivity and specificity of 8 6% and 95% respectively for ADC with cut off of 1.78 x 10-3 
mm2/s. They assessed minimum ADC value in their study unlike our study where we 
assessed mean ADC value. Similarly, Uto et al (51) in their study of 28 patients, showed a 
sensitivity and specificity of 83.3% and 90% respectively for a cut-off  LSR value of 1.135  
to differentiate benign lesion and lung cancer. They did not find any significant difference in 
ADC value between lung cancer and benign lesions. They explained that ADC assess pure 
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diffusion phenomenon whereas signal intensity on DWI is a combined effect of lower 
diffusion and T2 elongation. In our study, the LSR and ADC quantification showed no 
significant statistical difference in the diagnostic performance unlike study of Uto et al (51).  
  
Among the 20 cases of malignant lesions, the two outliers were both cases of adenocarcinoma 
which showed no diffusion restriction with ADC values of 2.041 and 1.799 X 10-3 mm2/s (>95th 
centile) respectively. In case of mucinous adenocarcinoma, this difference may be accounted 
for by their distinctive histopathological features. More cellular malignancies have more 
closely packed cells with a higher nuclear: cytoplasmic ratio. Mucinous adenocarcinoma, 
however, contains columnar cells (also known as goblet cells) which contain abundant mucin 
in the intracellular compartment and the cells are arranged in a lepidic pattern giving it the 
appearance of a consolidation (hence its former name bronchoalveolar carcinoma) and giving 
it a much higher signal intensity on DWI with no restriction of diffusion. Two cases of 
squamous cell carcinoma had ADC values above the cut-off in our study, although not as high 
as mucinous adenocarcinoma. 
Among the benign lesions, those that showed an ADC value lower than the cut-off included a 
few cases benign lesions of tuberculosis (2/11), fungal infection (1/3) and a case of 
amyloidosis. With respect to the cases of tuberculosis, this was comparable to a study 
performed by Gupta et al (68) which looked at 70 cases of tuberculomas and tubercular 
abscesses and found that the cores of the both lesions showed low ADC values with no 
significant difference between the two groups and they attributed it to the increased cellularity 
due to its inflammatory response. Similarly in the study by Uto et al, three cases of 
adenocarcinoma were false negative and one case of organising pneumonia was false positive.  
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Among the 5 of 20 malignant lesions and 12 of 27 benign lesions that showed necrosis in our 
study,  a higher mean ADC value within the necrotic component was seen in malignant 
lesions (1.880 x 10-3 mm2/s) as compared to benign lesions (1.284 x 10-3 mm2/s). The 
difference, however was not found to be statistically significant (p value= 0.132). Studies that 
looked at the role of diffusion weighted imaging in differentiating brain abscesses from 
necrotic gliobastomas in the brain found that necrotic cores within pyogenic abscesses had 
lower ADC values than that of necrotic tumours. This was attributed to the fact that the 
structure of pus itself is, perhaps, responsible for it due to its high cellularity, viscosity and 
fibrinogen content which severely impairs the mobility of water molecules within (69). The 
number of cases with necrosis in our study may have been too small to achieve statistical 
significance.  
A meta-analysis of 11 such studies on diffusion weighted imaging of pulmonary lesions 
(comprising a total of 294 benign and 755 malignant lesions) by Chen et al (70) showed an 
overall, sensitivity of 82.8% and  specificity of 80.1%  and concluded that DWI is a fairly 
accurate non-invasive technique to distinguish between benign and malignant lesions. 
Another similar meta-analysis done by Shen at al (71) which looked at 31 studies with 
2368 pulmonary lesions showed that LSR showed a pooled sensitivity of 80% and specificity 
of 85% and ADC, a sensitivity of 84% and specificity of 84%. This was higher than the 
sensitivity and specificity of 70% and 85.2% for LSR (b=1000 s/mm2) and 80% and 74.1% 
respectively for ADC, obtained from our study. 
 
Other imaging techniques like PET CT and perfusion studies may help in further 
characterization of benign versus malignant lesions. Ohno et al (61) studied PET CT versus 
CT perfusion in 76 pulmonary nodules (43 benign and 27 malignant) and found a sensitivity 
and specificity of 91% and 52% respectively for a SUVmax threshold value of 2 and  a 
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sensitivity and specificity of 86% and 54% respectively for a BVPP threshold value of 2. 
Although the sensitivity of PET CT is good for identifying malignancy, the specificity is less 
with false positive results. Many infections, tuberculosis and granulomas may show as false 
positive on PET CT. Moreover, PET CT is not widely available and involves the use of 
radioisotopes and contrast media. The specificity of our study was higher with comparable 
sensitivity than that of PET-CT and dynamic first pass CECT perfusion study by Ohno et al. 
 
The strength of our study, unlike others prior to it lies in its application on lesions that 
appeared indeterminate on CECT and not those that could be diagnosed as benign or 
malignant with confidence on CECT. Further DWI is a fast MRI sequence with no need for 
contrast injection. Our study reveals the added role of DWI in the diagnosis of pulmonary 
lesions which are indeterminate on CECT of thorax. This is especially relevant in patients 
with high risk for biopsy. 
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CONCLUSIONS 
 
 
 MRI with diffusion weighted imaging is a useful tool for further non-invasive 
evaluation of pulmonary lesions which are indeterminate on CECT thorax. 
 There is a significant difference between benign and malignant pulmonary lesions 
with regard to 
o Absolute signal intensity on DWI (b=1000 s/ mm2) (p value=0.002) 
o Lesion to spinal cord ratio (LSR) on b=500 s/ mm2 images (cut-off value= 
1.234; Sensitivity = 70%; Specificity = 74.1%; AUC = 0.761 and value above 
the cut-off is suggestive of malignancy) 
o LSR on b=1000 s/ mm2 images (cut-off value= 1.141; Sensitivity = 70%; 
Specificity = 85.2%; AUC = 0.765 and value above the cut-off is suggestive of 
malignancy) 
 Mean ADC of the solid component (cut-off value=1.248 x 103 mm2 /s; 
Sensitivity=80.1%; Specificity=74.1%; AUC=0.705 and value below the cut-off is 
suggestive of malignancy.  
 If both LSR and ADC are taken together as criteria for malignancy, the sensitivity of 
diagnosing malignancy is 56 % with specificity of ~96.2%. Instead, if either LSR or 
ADC is taken alone, the sensitivity of diagnosing malignancy increases to 94%, 
however, at the expense of a specificity which is reduced to ~63.1%. 
 The LSR (b=500 s/ mm2 and 1000 s/ mm2) and ADC quantification of the solid 
component have similar diagnostic performance for differentiating malignant and 
benign lesions. 
 There was no significant difference found between benign and malignant pulmonary 
lesions with regard to  
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o Absolute signal intensity of lesion on DWI (b=500 s/ mm2) 
o ADC of the necrotic components of the lesions  
 Mucinous adenocarcinoma show very high ADC values above the cut- off value, 
similar to benign lesions.  
 A few cases of benign lesions such as tuberculosis, fungal infection and amyloidosis 
may show ADC values lower than that of the cut-off value.  
 Although histopathological confirmation remains the gold-standard for diagnosis of 
indeterminate pulmonary lesions, in patients with high risk associated with lung 
biopsy, a prior knowledge of the likelihood of malignancy based on DWI can help to 
decide regarding trial antimicrobial therapy or biopsy with increased risk. 
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LIMITATIONS 
 
 There is a possible selection bias in this study as it conducted in a tertiary care centre 
with referral of a higher percentage of patients with pulmonary lesions that may not 
be representative of the general disease distribution.  
 The diagnoses of four of our cases were obtained using a combination of clinical data 
and short term follow up. 
 Avoiding susceptibility artefacts on diffusion weighted images in the pulmonary 
lesion due to air within the lesion and in the surrounding lung parenchyma is a 
challenge. This could have potentially affected the values obtained from them, 
lowering the diagnostic performance and area under the ROC curve.  
 Number of patients within the subgroups of benign and malignant lesions were 
insufficient for analysis of statistical significance within the group.  
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APPENDIX 1: CASE REPORT FORM 
 
STUDY TITLE:  Role of DWI and ADC quantification in the evaluation of pulmonary lesions which 
are indeterminate on Contrast Enhanced Computed Tomography 
1.  
2.  
                            First name                      middle name                  surname 
3.  
4.  
5.  
6. -male; 2-female) 
7. Referring department: 
-Gen.medicine; 2-Pulm. medicine; 3-Med. oncology; 4-Cardiothoracic Surg.) 
8. -not done; 1-done) 
9. Biopsy technique: 
-not applicable; 1-CT guided;  2- 
bronchoscopic; 3-open;  4-USG guided; 5- others) 
10. Histopathology report- 
- not applicable; 1-infection; 2-malignancy; 3-indeterminate; 4-
others) 
11. If histopathology report- 2( malignancy),                                                                             
(0- not applicable; 1- adenocarcinoma; 2-squamous cell carcinoma; 3- small cell carcinoma ; 
4- undifferentiated; 5-other primary tumour; 6- metastasis) ;               For 5, please 
specify__________________________________________ 
12. If histopathology report-2, Histological type-                          
(0- not applicable; 1- positive; 7-negative)    
13. - not performed ; 1- positive; 7-negative)                 
14. -not performed; 1-positive; 7-negative) 
15. - not performed; 1- mycobacterial; 2-other bacterial; 3-fungal; 7-
negative);     If other bacterial( 2), specify_____________ 
16. - not performed; 1- mycobacterial; 2-other bacterial; 3-fungal; 7-
negative);     If other bacterial( 2), specify_____________ 
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17. MRDWI of lesion compared to thoracic skeletal muscle ( b- -
hypointense; 2-isointense; 3-  
18. MRDWI of lesion compared to thoracic skeletal muscle ( b- -
hypointense; 2-isointense; 3-hyperintense) 
 
19. Lesion to spinal cord ratio (b-500) -  
20. Lesion to spinal cord ratio (b-1000) -  
21. ADC ( Apparent diffusion coefficient)- Solid component without necrosis/ air foci -
-3 mm/s² 
22. Is necrotic componen -yes; 2-  
23. ADC ( Apparent diffusion coefficient)-Necrotic component (if present)-  -3 
mm/s² 
24. -yes; 2-  
25. In case of all lab/histology test results being negative/ inconclusive, was resolution/ reduction 
of les   (0-not applicable; 1-yes; 2-no) 
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APPENDIX 2: INFORMATION SHEET AND CONSENT FORM 
 
PATIENT INFORMATION SHEET 
 
Study title:  
A study to assess the role of Diffusion weighted magnetic resonance imaging 
(DWMRI) and Apparent Diffusion Coefficient (ADC) quantification in the evaluation of 
indeterminate pulmonary lesions  
Purpose of the study 
The purpose of this study is to use certain non-invasive imaging techniques in MRI to 
obtain further information regarding the diagnosis of the lung mass detected on CT and 
compare and correlate it with the final diagnosis which may be obtained through biopsy, 
blood or sputum tests or on assessment of response to treatment on follow up. If found to be 
significant, this non-invasive method, although not a substitute for biopsy, could pre-
emptively help obtain a working diagnosis for patients who are either unable to or unwilling 
to undergo the same.  
Confidentiality 
The participation in the study will remain confidential and shall be known only to the 
investigators. 
 
Withdrawal from the study 
Participation in this study is purely voluntary and you can withdraw from the study 
anytime 
without any reason. It will not compromise your treatment in any way. There won’t be any 
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other risks involved in this study. You need not pay any extra money for the test as the cost 
will be borne by the research fund.  
For any queries, kindly contact-  
Dr Shweta Singh,  
PG Registrar,  
Department of Radiology,  
CMC Vellore. 
Mobile-+919972824127 
 
Detailed information about the Procedure 
What is magnetic resonance imaging, Diffusion weighted imaging and ADC 
quantification? 
The magnetic resonance imaging (MRI) machine is a tube with a centre opening that 
is about three feet wide. A table slides into the central opening and the patient lies on the 
table. Pictures of the chest are created using a magnetic field, radio waves and computers. 
No X-rays are used to create the images. The images made by the MRI will allow your doctor 
to look at the anatomy of the chest and any masses present within the lung. Additionally, 
diffusion weighted imaging further helps characterize this mass based on the motion of water 
molecules within the lung tissue and the lung mass and Apparent Diffusion Coefficient 
mapping helps objectively quantify it to assess whether the mass is likely to be cancerous or 
not.  
 
What are the benefits and risks of the MRI test? 
This test will potentially help your doctor diagnose the cause of the lung lesion detected on 
CT. There is no added risks of the test and no ionizing radiation or dye is used. If you should 
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experience any difficulty or discomfort during the test, the technician can be alerted 
immediately. There is also no added expense for the patient to undergo MRI.   
 
Before the test 
 There are no dietary restriction prior to the scan other than those advised to you based on 
your underlying medical condition  
 Take your medications as instructed by your doctor. 
 
The day of the test 
• The test takes about 8-9 minutes. Please allow at least 2 to 3 hours from the time you 
arrive to the time you leave. 
• Please arrive at MRI Room 3 or ASHA MRI room 6 as instructed, 30 minutes prior to the 
scheduled test time. 
• You will be asked to change into a hospital gown and remove all jewellery, dentures and 
hearing aids. 
• Before the test starts, you will be asked questions about your medical history. This is to 
make sure it is safe for you to have an MRI scan. The procedure will also be explained to 
you. 
• You will be moved onto a table that goes into the MRI scanner. 
 
During the test 
• The MRI scan will last for ~ 10 minutes  
• You will be asked to lie down still on your back within the gantry which will move into 
the MRI machine  
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• During the test, you will hear knocking sounds as the machine takes the pictures. We will 
also prompt you with instructions. For example, we may ask you to hold your breath for 8 
to10 seconds at a time. 
• It is important for you to stay as still as possible because movements can create glitches in 
the pictures. 
After the test 
• You may resume your normal activity unless your doctor tells you differently. 
• Take your regular medications as directed unless your doctor tells you differently. 
• By the following day, the test results will be sent to the doctor who ordered the test. You 
will need to contact your doctor to discuss the results of your test. 
• You will then be asked to undergo the scheduled blood or sputum tests with or without a 
lung biopsy of the lesion or will be subjected to follow up to assess the response to 
treatment with antibiotics or steroids, if administered 
• Keep any scheduled follow-up appointments with your primary doctor 
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WRITTEN INFORMED CONSENT FORM 
Study title: Assessment of indeterminate lung lesions using Magnetic Resonance Imaging 
(Diffusion weighted imaging and Apparent Diffusion Coefficient)  
Study Number:_____________         
Subject’s initials: _________________ 
Subject’s name:______________________ 
Date of Birth/ Age:_____________________ 
i) I confirm that I have read and understood the information sheet dated____________ for the 
above study and have had the opportunity to ask questions [  ] 
ii) I understand that my participation is voluntary and that I am free to withdraw at any time, 
without any reason, without my medical care being affected.[  ] 
iii) I understand that the Sponsor of the clinical trial, the Ethics committee and the regulatory 
authorities will not need my permission to look at my health records both in respect of the 
current study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my identity will 
not be revealed in any information released to third parties or published. [  ] 
iv) I agree not to restrict the use of any data or results that arise from this study provided such 
a use is for scientific purpose(s) 
v) I agree to take part in the above study. [   ] 
 
Signature/ thumb impression of subject: 
Date:  _____/____/______ 
Signatory’s name: ____________________________ 
Signature:                                      
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 Or :  
 
 
 
 
Representative:________________________ 
Date:  _____/____/______ 
Signatory’s name: __________________________ 
Signature of the investigator:____________________ 
Date:  _____/____/______ 
Study investigator’s name: ____________________ 
Signature/ thumb impression of the witness: _______________________ 
Date:  _____/____/______ 
Name and address of the witness:  
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APPENDIX 4: IRB AND ETHICS COMMITTEE APPROVAL 
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